Prevalence, Characteristics and Outcomes of Older Patients with Hereditary Versus Wild-Type Transthyretin Amyloid Cardiomyopathy
Aldostefano Porcari(Azienda Sanitaria Universitaria Integrata di Trieste), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Gianfranco Sinagra(Società Italiana di Cardiologia), Lucia Venneri(MACOM (United States)), Philip N. Hawkins(The Royal Free Hospital), Janet A. Gilbertson(The Royal Free Hospital), Marianna Fontana(Amyloidosis Foundation), Rishi Patel(Texas Tech University), Ambra Masi(MACOM (United States)), Marco Merlo(Universidade da Coruña), Carol Whelan(The Royal Free Hospital), Ashutosh Wechalekar(University College Hospital), Yousuf Razvi(The Royal Free Hospital), Muhammad U. Rauf(The Royal Free Hospital), Candida Cristina Quarta(Boston University), David F. Hutt(Boston University), Adam Ioannou(The Royal Free Hospital), Ana Martinez–Naharro(Children's Cancer and Leukaemia Group), Dorota Rowczenio(Children's Cancer and Leukaemia Group)
Cited by 97
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
Truncations of Titin Causing Dilated Cardiomyopathy
|New England Journal of Medicine|2012|1.5k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k